Cargando…
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells
Occurrence of an inherent or acquired resistance to the chemotherapeutic drug docetaxel is a major burden for patients suffering from different kinds of malignancies, including castration resistant prostate cancer (PCa). In the present study we address the question whether PIAS1 targeting can be use...
Autores principales: | Puhr, Martin, Hoefer, Julia, Neuwirt, Hannes, Eder, Iris E., Kern, Johann, Schäfer, Georg, Geley, Stephan, Heidegger, Isabel, Klocker, Helmut, Culig, Zoran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322998/ https://www.ncbi.nlm.nih.gov/pubmed/25474038 |
Ejemplares similares
-
SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer
por: Hoefer, Julia, et al.
Publicado: (2014) -
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo
por: Ofer, Philipp, et al.
Publicado: (2015) -
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016) -
PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer
por: Puhr, M, et al.
Publicado: (2016) -
p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer
por: Gruber, Martina, et al.
Publicado: (2020)